ABVC
ABVC BioPharma, Inc.
Price Chart
Latest Quote
$1.33
-0.11 (-7.64%)
Current Price
| Previous Close | $1.44 |
| Open | $1.41 |
| Day High | $1.48 |
| Day Low | $1.29 |
| Volume | 179,182 |
Stock Information
| Shares Outstanding | 26.00M |
| Total Debt | $2.73M |
| Cash Equivalents | $203K |
| Net Income | $-8.63M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $34.58M |
| EPS (TTM) | $-0.39 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $38.19M |
| Income | $-8.63M |
| Book/sh | $0.43 |
| Cash/sh | $0.01 |
| Employees | 16 |
Financial Ratios
| Quick Ratio | 0.04 |
| Current Ratio | 0.12 |
| Debt/Eq | 21.29 |
Returns & Margins
| ROA | -29.01% |
| ROE | -87.78% |
Ownership
| Insider Ownership | 18.57% |
| Institutional Ownership | 3.14% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -3.02 |
| P/B | 3.09 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $1.20 |
| SMA50 | $1.19 |
| SMA200 | $2.06 |
| RSI | 64.63 |
| ATR | 0.1454 |
| Shares Float | 20.44M |
| Short Float | 1.29% |
| Short Ratio | 3.64 |
| Volatility | 0.57 |
| Rel Volume | 1.42 |
Performance History
| Week | -5.67% |
| Month | +20.91% |
| Quarter | -0.75% |
| 6 Months | -48.25% |
| YTD | -39.27% |
| Year | -15.82% |
| 3 Years | -80.44% |
| 5 Years | -97.58% |
| 10 Years | -99.63% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-05 | $1.33 | 180,190 |
| 2026-06-04 | $1.44 | 192,300 |
| 2026-06-03 | $1.28 | 130,600 |
| 2026-06-02 | $1.25 | 110,500 |
| 2026-06-01 | $1.36 | 144,600 |
| 2026-05-29 | $1.41 | 91,400 |
| 2026-05-28 | $1.41 | 143,700 |
| 2026-05-27 | $1.39 | 232,000 |
| 2026-05-26 | $1.29 | 204,400 |
| 2026-05-22 | $1.14 | 252,700 |
| 2026-05-21 | $1.11 | 118,700 |
| 2026-05-20 | $1.10 | 78,900 |
| 2026-05-19 | $1.10 | 66,700 |
| 2026-05-18 | $1.07 | 129,700 |
| 2026-05-15 | $1.09 | 68,600 |
| 2026-05-14 | $1.08 | 76,400 |
| 2026-05-13 | $1.07 | 96,700 |
| 2026-05-12 | $1.05 | 79,200 |
| 2026-05-11 | $1.02 | 78,200 |
| 2026-05-08 | $1.06 | 67,700 |
| 2026-05-07 | $1.10 | 73,600 |
| 2026-05-06 | $1.10 | 159,700 |
About ABVC BioPharma, Inc.
ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601, which is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus, which is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer; ABV-2001, an intraocular irrigation solution; ABV-2002, a corneal Storage Solution; and ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer. The company has a co-development agreement with Rgene Corporation and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $0 | $763 | $302,037 | $286,415 |
| Cost Of Revenue | $0 | $763 | $302,037 | $286,415 |
| Total Revenue | $0 | $509,589 | $152,430 | $969,783 |
| Operating Revenue | $0 | $509,589 | $152,430 | $969,783 |
| Expenses | ||||
| Interest Expense | $415,890 | $825,899 | $1,313,671 | $293,968 |
| Total Expenses | $7,151,259 | $5,214,831 | $6,919,164 | $16,084,195 |
| Other Income Expense | $-952,759 | $74,207 | $-129,914 | $-294,033 |
| Other Non Operating Income Expenses | $120,554 | $182,921 | $69,284 | $83,001 |
| Net Non Operating Interest Income Expense | $-248,787 | $-738,541 | $-1,128,190 | $-106,151 |
| Interest Expense Non Operating | $415,890 | $825,899 | $1,313,671 | $293,968 |
| Operating Expense | $7,151,259 | $5,214,068 | $6,617,127 | $15,797,780 |
| General And Administrative Expense | $7,030,174 | $5,034,796 | $5,554,211 | $13,104,323 |
| Other Operating Expenses | - | - | - | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-7,908,554 | $-4,902,878 | $-7,788,050 | $-16,423,239 |
| Net Interest Income | $-248,787 | $-738,541 | $-1,128,190 | $-106,151 |
| Interest Income | $167,103 | $87,358 | $185,481 | $187,817 |
| Normalized Income | $-7,060,637 | $-4,796,402 | $-7,630,684 | $-16,125,382 |
| Net Income From Continuing And Discontinued Operation | $-7,908,554 | $-4,902,878 | $-7,788,050 | $-16,423,239 |
| Total Operating Income As Reported | $-7,151,259 | $-4,705,242 | $-6,766,734 | $-15,114,412 |
| Net Income Common Stockholders | $-7,908,554 | $-4,902,878 | $-7,788,050 | $-16,423,239 |
| Net Income | $-7,908,554 | $-4,902,878 | $-7,788,050 | $-16,423,239 |
| Net Income Including Noncontrolling Interests | $-8,376,959 | $-5,259,037 | $-8,280,844 | $-16,312,374 |
| Net Income Continuous Operations | $-8,376,959 | $-5,259,037 | $-8,280,844 | $-16,312,374 |
| Pretax Income | $-8,352,805 | $-5,369,576 | $-8,024,838 | $-15,514,596 |
| Special Income Charges | $-803,008 | $255,592 | $0 | $-110,125 |
| Interest Income Non Operating | $167,103 | $87,358 | $185,481 | $187,817 |
| Operating Income | $-7,151,259 | $-4,705,242 | $-6,766,734 | $-15,114,412 |
| Gross Profit | $0 | $508,826 | $-149,607 | $683,368 |
| Per Share | ||||
| Diluted EPS | - | $-0.42 | $-1.80 | $-5.20 |
| Basic EPS | - | $-0.42 | $-1.80 | $-5.20 |
| Other | ||||
| Tax Effect Of Unusual Items | $-225,396 | $-2,238 | $-41,832 | $-79,177 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-6,358,768 | $-4,234,042 | $-6,131,579 | $-14,819,795 |
| Total Unusual Items | $-1,073,313 | $-108,714 | $-199,198 | $-377,034 |
| Total Unusual Items Excluding Goodwill | $-1,073,313 | $-108,714 | $-199,198 | $-377,034 |
| Reconciled Depreciation | $504,834 | $200,921 | $380,390 | $23,799 |
| EBITDA (Bullshit earnings) | $-7,432,081 | $-4,342,756 | $-6,330,777 | $-15,196,829 |
| EBIT | $-7,936,915 | $-4,543,677 | $-6,711,167 | $-15,220,628 |
| Diluted NI Availto Com Stockholders | $-7,908,554 | $-4,902,878 | $-7,788,050 | $-16,423,239 |
| Minority Interests | $468,405 | $356,159 | $492,794 | $-110,865 |
| Tax Provision | $24,154 | $-110,539 | $256,006 | $797,778 |
| Write Off | $803,008 | $0 | $0 | $110,125 |
| Gain On Sale Of Security | $-270,305 | $-364,306 | $-199,198 | $-266,909 |
| Research And Development | $121,085 | $179,272 | $1,062,916 | $2,693,457 |
| Selling General And Administration | $7,030,174 | $5,034,796 | $5,554,211 | $13,104,323 |
| Other Gand A | $2,887,358 | $2,261,336 | $5,368,278 | $6,067,545 |
| Salaries And Wages | $4,142,816 | $2,773,460 | $185,933 | $7,036,778 |
| Diluted Average Shares | - | $11,673,980 | $4,335,650 | $3,166,466 |
| Basic Average Shares | - | $11,673,980 | $4,335,650 | $3,166,466 |
| Other Special Charges | - | $-255,592 | - | - |
Fetched: 2026-06-02
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $11,111,861 | $1,226,140 | $1,554,110 | $3,098,585 |
| Total Assets | $21,062,203 | $7,539,907 | $7,784,499 | $9,579,574 |
| Total Non Current Assets | $18,560,860 | $5,360,092 | $6,127,790 | $6,592,327 |
| Other Non Current Assets | $116,966 | $133,121 | $141,231 | - |
| Non Current Prepaid Assets | $1,816,742 | $1,816,742 | $1,966,742 | $3,032,551 |
| Investmentin Financial Assets | $28,741 | $790,250 | $847,252 | $842,070 |
| Current Assets | $2,501,343 | $2,179,815 | $1,656,709 | $2,987,247 |
| Other Current Assets | $346,616 | $96,213 | $101,051 | $150,235 |
| Restricted Cash | $645,505 | $615,433 | $656,625 | $1,306,463 |
| Receivables | $763,388 | $1,155,051 | $759,566 | $1,369,487 |
| Cash Cash Equivalents And Short Term Investments | $745,834 | $313,118 | $139,467 | $161,062 |
| Cash And Cash Equivalents | $681,480 | $248,382 | $60,155 | $85,265 |
| Accounts Receivable | - | $0 | $1,530 | $98,325 |
| Allowance For Doubtful Accounts Receivable | - | $-616,414 | $-616,505 | - |
| Gross Accounts Receivable | - | $616,414 | $618,035 | - |
| Non Current Deferred Assets | - | - | $0 | $117,110 |
| Non Current Deferred Taxes Assets | - | - | $0 | $117,110 |
| Non Current Accounts Receivable | - | - | $113,516 | $865,477 |
| Inventory | - | - | - | $0 |
| Goodwill And Other Intangible Assets | - | - | - | - |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Net Debt | $873,042 | $1,541,916 | $1,725,617 | $1,808,485 |
| Total Debt | $3,472,826 | $2,430,686 | $2,595,055 | $3,054,891 |
| Long Term Debt And Capital Lease Obligation | $1,600,747 | $236,807 | $407,457 | $791,827 |
| Current Debt And Capital Lease Obligation | $1,872,079 | $2,193,879 | $2,187,598 | $2,263,064 |
| Current Debt | $1,554,522 | $1,790,298 | $1,785,772 | $1,893,750 |
| Other Current Borrowings | $799,010 | $950,046 | $886,522 | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $7,764,723 | $6,815,948 | $6,531,026 | $6,343,435 |
| Total Non Current Liabilities Net Minority Interest | $1,600,747 | $258,487 | $429,137 | $799,806 |
| Current Liabilities | $6,163,976 | $6,557,461 | $6,101,889 | $5,543,629 |
| Other Current Liabilities | $470,133 | $430,107 | $427,350 | $468,150 |
| Current Deferred Liabilities | $12,600 | $81,115 | $79,500 | $10,985 |
| Current Notes Payable | $30,000 | $30,000 | $0 | - |
| Payables And Accrued Expenses | $2,364,127 | $2,700,387 | $2,360,050 | $2,232,565 |
| Payables | $117,668 | $773,045 | $286,439 | $359,992 |
| Total Tax Payable | $11,964 | $0 | $112,946 | $0 |
| Other Non Current Liabilities | - | $21,680 | $21,680 | $7,979 |
| Accounts Payable | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $11,111,861 | $1,226,140 | $1,554,110 | $3,098,585 |
| Total Equity Gross Minority Interest | $13,297,480 | $723,959 | $1,253,473 | $3,236,139 |
| Stockholders Equity | $11,111,861 | $1,226,140 | $1,554,110 | $3,098,585 |
| Other Equity Interest | $359,000 | $31,040 | $-451,480 | $-1,354,440 |
| Gains Losses Not Affecting Retained Earnings | $487,602 | $445,665 | $516,387 | $517,128 |
| Other Equity Adjustments | $487,602 | $445,665 | $516,387 | $517,128 |
| Retained Earnings | $-76,858,361 | $-68,949,807 | $-64,046,929 | $-54,904,439 |
| Long Term Equity Investment | $1,849,724 | $1,468,504 | $1,680,488 | $0 |
| Other | ||||
| Treasury Shares Number | $730,641 | $730,641 | $26,553 | $27,534 |
| Ordinary Shares Number | $24,322,552 | $13,137,843 | $7,913,745 | $3,285,732 |
| Share Issued | $25,053,193 | $13,868,484 | $7,940,298 | $3,313,266 |
| Tangible Book Value | $11,111,861 | $1,226,140 | $1,554,110 | $3,098,585 |
| Invested Capital | $12,666,383 | $3,016,438 | $3,339,882 | $4,992,335 |
| Working Capital | $-3,662,633 | $-4,377,646 | $-4,445,180 | $-2,556,382 |
| Capital Lease Obligations | $1,918,304 | $640,388 | $809,283 | $1,161,141 |
| Total Capitalization | $11,111,861 | $1,226,140 | $1,554,110 | $3,098,585 |
| Minority Interest | $2,185,619 | $-502,181 | $-300,637 | $137,554 |
| Treasury Stock | $8,909,691 | $8,909,691 | $8,901,668 | $9,100,000 |
| Additional Paid In Capital | $96,008,258 | $78,595,065 | $73,978,380 | $67,937,050 |
| Capital Stock | $25,053 | $13,868 | $7,940 | $3,286 |
| Common Stock | $25,053 | $13,868 | $7,940 | $3,286 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $1,600,747 | $236,807 | $407,457 | $791,827 |
| Current Deferred Revenue | $12,600 | $81,115 | $79,500 | $10,985 |
| Current Capital Lease Obligation | $317,557 | $403,581 | $401,826 | $369,314 |
| Line Of Credit | $725,512 | $810,252 | $899,250 | $1,893,750 |
| Pensionand Other Post Retirement Benefit Plans Current | $1,445,037 | $1,151,973 | $1,047,391 | $568,865 |
| Current Accrued Expenses | $2,246,459 | $1,927,342 | $2,073,611 | $1,872,573 |
| Dueto Related Parties Current | $105,704 | $773,045 | $173,493 | $359,992 |
| Investments And Advances | $1,878,465 | $2,258,754 | $2,527,740 | $842,070 |
| Available For Sale Securities | $28,741 | $790,250 | $847,252 | $842,070 |
| Investmentsin Joint Venturesat Cost | $0 | $0 | - | - |
| Investmentsin Associatesat Cost | $1,849,724 | $1,468,504 | $1,680,488 | $0 |
| Net PPE | $14,748,687 | $1,151,475 | $1,378,561 | $1,735,119 |
| Accumulated Depreciation | $-3,380,097 | $-3,341,739 | $-3,335,041 | $-3,304,457 |
| Gross PPE | $18,128,784 | $4,493,214 | $4,713,602 | $5,039,576 |
| Other Properties | $1,913,278 | $640,387 | $809,283 | $1,161,141 |
| Machinery Furniture Equipment | $1,305,757 | $1,294,617 | $1,313,472 | $1,290,555 |
| Buildings And Improvements | $2,224,082 | $2,219,244 | $2,227,431 | $2,226,687 |
| Land And Improvements | $12,685,667 | $338,966 | $363,416 | $361,193 |
| Properties | $0 | $0 | $0 | $0 |
| Duefrom Related Parties Current | $763,388 | $1,155,051 | $758,036 | $1,271,162 |
| Other Short Term Investments | $64,354 | $64,736 | $79,312 | $75,797 |
| Duefrom Related Parties Non Current | - | $0 | $113,516 | $865,477 |
| Other Investments | - | - | $847,252 | $842,070 |
| Construction In Progress | - | - | $7,400,000 | $0 |
| Inventories Adjustments Allowances | - | - | - | $0 |
| Finished Goods | - | - | - | $0 |
| Work In Process | - | - | - | $0 |
| Raw Materials | - | - | - | $0 |
| Goodwill | - | - | - | - |
Fetched: 2026-06-02
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-2,986,299 | $-1,809,145 | $-4,208,049 | $-7,518,083 |
| Operating Activities | ||||
| Operating Cash Flow | $-2,986,299 | $-1,809,145 | $-4,186,848 | $-7,398,391 |
| Cash Flow From Continuing Operating Activities | $-2,986,299 | $-1,809,145 | $-4,186,848 | $-7,398,391 |
| Operating Gains Losses | $192,759 | $339,171 | $221,888 | - |
| Investing Activities | ||||
| Investing Cash Flow | $-1,208,790 | $0 | $-360,186 | $-1,721,684 |
| Cash Flow From Continuing Investing Activities | $-1,208,790 | $0 | $-360,186 | $-1,721,684 |
| Net Other Investing Changes | $-1,202,996 | - | - | - |
| Capital Expenditure | - | - | $-21,201 | $-119,692 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $0 | $-7,320 | $0 | - |
| Issuance Of Capital Stock | $3,305,303 | $31,040 | $1,050,000 | $3,663,925 |
| Financing Cash Flow | $4,637,995 | $1,980,769 | $3,869,961 | $4,013,925 |
| Cash Flow From Continuing Financing Activities | $4,637,995 | $1,980,769 | $3,869,961 | $4,013,925 |
| Net Common Stock Issuance | $3,305,303 | $23,720 | $1,050,000 | $3,663,925 |
| Common Stock Issuance | $3,305,303 | $31,040 | $1,050,000 | $3,663,925 |
| Net Other Financing Charges | - | $599,552 | $-48,999 | - |
| Other | ||||
| Repayment Of Debt | $-547,684 | $-356,169 | $-1,000,000 | $0 |
| Issuance Of Debt | $889,010 | $372,095 | $1,462,622 | $350,000 |
| Interest Paid Supplemental Data | $31,518 | $22,539 | $33,180 | $285,465 |
| Income Tax Paid Supplemental Data | $12,077 | $25,863 | $27,392 | $1,600 |
| End Cash Position | $1,326,985 | $863,815 | $716,780 | $1,391,728 |
| Beginning Cash Position | $863,815 | $716,780 | $1,391,728 | $6,565,215 |
| Effect Of Exchange Rate Changes | $20,264 | $-24,589 | $2,125 | $-67,337 |
| Changes In Cash | $442,906 | $171,624 | $-677,073 | $-5,106,150 |
| Proceeds From Stock Option Exercised | $991,366 | $1,341,571 | $2,406,338 | $0 |
| Common Stock Payments | $0 | $-7,320 | $0 | - |
| Net Issuance Payments Of Debt | $341,326 | $15,926 | $462,622 | $350,000 |
| Net Short Term Debt Issuance | $378,610 | $312,943 | $462,622 | $350,000 |
| Short Term Debt Payments | $-120,400 | $-29,152 | $-1,000,000 | $0 |
| Short Term Debt Issuance | $499,010 | $342,095 | $1,462,622 | $350,000 |
| Net Long Term Debt Issuance | $-37,284 | $-297,017 | $0 | $0 |
| Long Term Debt Payments | $-427,284 | $-327,017 | $0 | $0 |
| Long Term Debt Issuance | $390,000 | $30,000 | $0 | $0 |
| Net Investment Properties Purchase And Sale | $-5,794 | $0 | - | - |
| Purchase Of Investment Properties | $-5,794 | $0 | - | - |
| Change In Working Capital | $-615,302 | $-408,422 | $490,771 | $635,565 |
| Change In Other Working Capital | $-85,380 | $1,615 | $82,215 | $-2,600 |
| Change In Other Current Liabilities | $-474,479 | $-168,896 | $-351,859 | $-2,600 |
| Change In Payables And Accrued Expense | $164,171 | $39,873 | $751,708 | $1,851,253 |
| Change In Accrued Expense | $152,207 | $152,819 | $638,762 | $1,608,784 |
| Change In Payable | $11,964 | $-112,946 | $112,946 | $242,469 |
| Change In Tax Payable | $11,964 | $-112,946 | $112,946 | $0 |
| Change In Income Tax Payable | $11,964 | $-112,946 | $112,946 | $0 |
| Change In Prepaid Assets | $-71,653 | $12,948 | $101,926 | $238,092 |
| Change In Inventory | $-11,460 | $0 | - | $0 |
| Change In Receivables | $-136,501 | $-293,962 | $-93,219 | $-1,451,180 |
| Other Non Cash Items | $351,085 | $532,769 | $1,244,245 | $32,350 |
| Stock Based Compensation | $4,142,816 | $2,773,460 | $185,933 | $7,036,778 |
| Provisionand Write Offof Assets | $0 | $11,993 | $1,455,101 | $210,564 |
| Asset Impairment Charge | $814,468 | $0 | $0 | $110,125 |
| Depreciation Amortization Depletion | $504,834 | $200,921 | $380,390 | $23,799 |
| Depreciation And Amortization | $504,834 | $200,921 | $380,390 | $23,799 |
| Depreciation | $504,834 | $200,921 | $380,390 | $23,799 |
| Gain Loss On Investment Securities | $192,759 | $339,171 | $221,888 | - |
| Net Income From Continuing Operations | $-8,376,959 | $-5,259,037 | $-8,280,844 | $-16,312,374 |
| Net Business Purchase And Sale | - | $0 | $-338,985 | $-1,601,992 |
| Purchase Of Business | - | $0 | $-338,985 | $-1,601,992 |
| Net PPE Purchase And Sale | - | $0 | $-21,201 | $-119,692 |
| Purchase Of PPE | - | $0 | $-21,201 | $-119,692 |
| Changes In Account Receivables | - | $0 | $228,557 | $-614,166 |
| Deferred Tax | - | $0 | $115,668 | $864,802 |
| Deferred Income Tax | - | $0 | $115,668 | $864,802 |
| Net Investment Purchase And Sale | - | - | - | $0 |
| Purchase Of Investment | - | - | - | $0 |
| Change In Interest Payable | - | - | - | $-2,600 |
| Change In Account Payable | - | - | - | $0 |
| Sale Of Investment | - | - | - | - |
Fetched: 2026-06-02